AVEO Pharmaceuticals, Inc.

AVEO Oncology, also known as AVEO Pharmaceuticals, Inc. , has begun to enrol patients in a Phase III clinical trial evaluating its candidate ficlatuzumab in combination with Erbitux (cetuximab) in pa

Although merger and acquisition activity in the South Korean biopharma sector is viewed as relatively timid compared to the global market, it seems to have increased notably since the end of the COVID

Major South Korean pharma companies reported mixed earnings in the first quarter ended 31 March, with Hanmi Pharmaceutical Co., Ltd. and Daewoong Pharmaceutical Company Ltd. continuing to perform

South Korean pharmas have been actively making investments in bioventures in recent years to find new growth engines. Now, they are taking a step further and joining hands with other pharmas to co-inv